Biyun Wang

4.2k total citations
148 papers, 2.7k citations indexed

About

Biyun Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Biyun Wang has authored 148 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 36 papers in Cancer Research. Recurrent topics in Biyun Wang's work include Cancer Treatment and Pharmacology (50 papers), HER2/EGFR in Cancer Research (47 papers) and Advanced Breast Cancer Therapies (34 papers). Biyun Wang is often cited by papers focused on Cancer Treatment and Pharmacology (50 papers), HER2/EGFR in Cancer Research (47 papers) and Advanced Breast Cancer Therapies (34 papers). Biyun Wang collaborates with scholars based in China, United States and Canada. Biyun Wang's co-authors include Xichun Hu, Leiping Wang, Jun Cao, Jian Zhang, Zhonghua Wang, Ziang Yang, Hong Wang, Zhonghua Wang, Zhimin Shao and Zhonghua Tao and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Biyun Wang

140 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Biyun Wang China	28	1.3k	863	796	665	288	148	2.7k
Reinhard von Roemeling United States	23	728 0.6×	626 0.7×	774 1.0×	606 0.9×	148 0.5×	72	2.0k
Jae Hong Seo South Korea	27	1.6k 1.3×	523 0.6×	859 1.1×	818 1.2×	260 0.9×	142	3.1k
Shyhmin Huang United States	23	1.5k 1.2×	1.0k 1.2×	1.1k 1.3×	291 0.4×	121 0.4×	39	2.4k
Ruth Heimann United States	25	970 0.8×	684 0.8×	908 1.1×	1.1k 1.6×	411 1.4×	69	2.8k
Helena Linardou Greece	27	1.8k 1.4×	1.2k 1.4×	899 1.1×	653 1.0×	237 0.8×	87	2.8k
Christian Dittrich Austria	33	1.6k 1.3×	833 1.0×	1.4k 1.8×	664 1.0×	299 1.0×	136	4.0k
Toru Mukohara Japan	28	2.3k 1.9×	1.7k 1.9×	1.7k 2.2×	577 0.9×	259 0.9×	128	4.1k
Zsuzsanna Pápai Hungary	20	1.7k 1.4×	1.6k 1.9×	1.2k 1.5×	951 1.4×	360 1.3×	94	3.2k
Chia‐Chi Lin Taiwan	25	2.1k 1.6×	1.3k 1.5×	799 1.0×	391 0.6×	312 1.1×	62	3.5k
George P. Stathopoulos Greece	28	1.4k 1.1×	457 0.5×	689 0.9×	395 0.6×	379 1.3×	105	2.6k

Countries citing papers authored by Biyun Wang

Since Specialization

Citations

This map shows the geographic impact of Biyun Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Biyun Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Biyun Wang more than expected).

Fields of papers citing papers by Biyun Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Biyun Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Biyun Wang. The network helps show where Biyun Wang may publish in the future.

Co-authorship network of co-authors of Biyun Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Biyun Wang. A scholar is included among the top collaborators of Biyun Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Biyun Wang. Biyun Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jin, Juan, Tiantian Liu, Mingchuan Zhao, et al.. (2025). Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy. Precision Clinical Medicine. 8(4). pbaf026–pbaf026.

Lü, Xue, et al.. (2025). Dynamic Self‐Optimizing Reconstruction of Stainless Steel Fe‐Ni Dual Sites Accelerates Catalytic Intermediate Coupling for High‐Efficiency Oxygen Evolution Reaction at Industrial Current Density. Advanced Functional Materials. 36(4). 1 indexed citations

Yang, Lili, et al.. (2024). Toxoplasma gondii infection positively associated with schizophrenia: Evidences from UK Biobank cohort and case-controlled studies. Journal of Psychiatric Research. 175. 243–250. 4 indexed citations

Wang, Biyun, Youyuan Chen, Zongtao Sun, et al.. (2024). Identification and Functional Analysis of the fruitless Gene in a Hemimetabolous Insect, Nilaparvata lugens. Insects. 15(4). 262–262. 5 indexed citations

Li, Bin, Ye Wang, Juan Jin, et al.. (2023). Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors. Cancer Communications. 43(9). 1003–1026. 8 indexed citations

Gong, Chengcheng, Yi Li, Yizhao Xie, et al.. (2023). Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer. Frontiers in Endocrinology. 14. 1270453–1270453. 6 indexed citations

Jin, Juan, Bin Li, Ting Li, et al.. (2023). Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. Journal of Translational Medicine. 21(1). 360–360. 18 indexed citations

Huang, Lei, Lili Shi, Chengcheng Gong, et al.. (2023). Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency. Cancer Research. 83(7_Supplement). 2702–2702. 8 indexed citations

Li, Wěi, Dongyan Cai, Chunxiao Sun, et al.. (2022). Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study. Therapeutic Advances in Medical Oncology. 14. 4287497264–4287497264. 5 indexed citations

10.

Li, Yaohua, Yannan Zhao, Wei Zhang, et al.. (2022). Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK. Oncogene. 41(41). 4658–4672. 7 indexed citations

11.

Zhang, Jian, Yanchun Meng, Biyun Wang, et al.. (2022). Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. Frontiers in Oncology. 12. 775081–775081. 11 indexed citations

12.

Wang, Leiping, Jun Cao, Chunlei Li, et al.. (2021). Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial. Investigational New Drugs. 40(2). 330–339. 26 indexed citations

13.

Yang, Fan, Xiang Huang, Chunxiao Sun, et al.. (2020). Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population. BMC Cancer. 20(1). 255–255. 9 indexed citations

14.

Lin, Ying, Mingxi Lin, Jian Zhang, et al.. (2020). Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis. Cancer Research and Treatment. 52(4). 1059–1066. 34 indexed citations

15.

Xie, Yizhao, Bingxin Gu, Xichun Hu, et al.. (2019). <p>Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method</p>. Cancer Management and Research. Volume 11. 6019–6027. 5 indexed citations

16.

Xie, Yizhao, Yi Li, Yinbin Zhang, et al.. (2019). Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study. Clinical Breast Cancer. 19(3). e452–e458. 4 indexed citations

17.

Li, Ting, Biyun Wang, Zhonghua Wang, et al.. (2015). Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. PLoS ONE. 10(7). e0133133–e0133133. 6 indexed citations

18.

Zhang, Jian, Li‐Xin Qiu, Zhonghua Wang, et al.. (2010). Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment. 124(2). 419–424. 18 indexed citations

19.

Wang, Jialei, Jin Li, Xiaonan Hong, et al.. (2007). Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncology. 44(5). 464–470. 29 indexed citations

20.

Guo, Ye, Jiade J. Lu, Xuejun Ma, et al.. (2007). Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: Elucidating the significance of systemic chemotherapy. Oral Oncology. 44(1). 23–30. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact